Norcross, GA, United States
Norcross, GA, United States

Time filter

Source Type

News Article | May 15, 2017
Site: www.prnewswire.com

•         Growth in the blood group typing market is primarily attributed to the increasing demand for blood and blood products, growing number of road accidents and trauma cases that necessitate blood transfusion, need for blood grouping during prenatal testing, and increasing usage of blood group typing in forensic sciences. •         Based on product and service, the market is segmented into consumables, instruments, and services. •         The consumables segment is further categorized into antisera reagents, anti-human globulin reagents, red blood cells reagents, and blood bank saline. The blood group typing market is projected to reach USD 3.12 billion by 2021 from USD 1.95 billion in 2016, at a CAGR of 9.8%. Growth in the blood group typing market is primarily attributed to the increasing demand for blood and blood products, growing number of road accidents and trauma cases that necessitate blood transfusion, need for blood grouping during prenatal testing, and increasing usage of blood group typing in forensic sciences. Stringent regulatory standards for blood transfusion are also expected to fuel the growth of the blood group typing market during the forecast period. Based on product and service, the market is segmented into consumables, instruments, and services. The consumables segment is further categorized into antisera reagents, anti-human globulin reagents, red blood cells reagents, and blood bank saline. The consumables segment is expected to grow at the highest CAGR during the forecast period. The increase in blood donation rates and major surgical procedures (including organ transplant procedures) are the key factors driving the growth of this segment. Based on test type, the market is segmented into antibody screening, HLA typing, cross-matching tests, ABO blood tests, and antigen typing. The antibody screening segment is expected to grow at the highest CAGR during the forecast period. The growth of this market segment is primarily driven by the increasing prevalence of chronic disorders and growing demand for the early diagnosis of diseases. Geographically, North America accounted for the largest share of the market in 2016. Growth in the North American segment is primarily driven by the rapid growth in the aging population, availability of reimbursement for several surgeries, and increasing incidence of major disorders. In addition, the high growth potential in the Asian region provides opportunities for players in the market. The major players in the market are Bio-Rad Laboratories, Inc. (U.S.), Grifols, S.A. (Spain), Immucor, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), Quotient, Ltd. (U.S.), ), Novacyt Group (France), BAG Healthcare GmbH (Germany), Rapid Labs (U.K.), Day medical SA (Switzerland), DIAGAST (France), and AXO Science (France). The blood group typing market is segmented based on product and service, technique, test type, end user, and region. Apart from comprehensive geographic & devices analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by players to maintain and increase their shares in the market. This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner greater market shares. Companies purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares. The report provides insights on the following pointers: Market Penetration: Comprehensive information on the product portfolios of the top players in the blood group typing market. Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the blood group typing market. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the blood group typing market. Market Development: Comprehensive information about emerging markets. This report analyzes the market for blood group typing products across geographies. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the blood group typing market. ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blood-group-typing-market-is-expected-grow-to-312-billion-usd-by-2021-300457898.html


News Article | May 22, 2017
Site: www.PR.com

Regulatory updates and key industry feedback from leading IVD manufacturers within the complex and ever-changing landscape. London, United Kingdom, May 22, 2017 --( Nations confirmed to attend include Belgium, France, Germany, Netherlands United Kingdom, UAE & USA. A snapshot of organisations confirmed to join include: Arkray Inc, Berlin Heart A G, BSI, Cytocell Ltd, Dekra, GS1, Immucor, IQ Products, Lifescan (J&J), LNE/G-MED, LRQA, Meridian Bioscience, MET, MHRA, Ortho Clinical Diagnostics, Procorre, Qarad Bvba, Qserve Consultancy, SPD Ltd., Tuv Rheinland, TUV SUD AB, UL International and more. View 2017 Attendee List The agenda will address questions such as: How can IVD manufacturers prepare for the new IVD regulation? How the change in classifications will impact the industry. What are the best strategies and approaches to meeting the requirements for clinical evidence? For those looking to attend there is currently a £100 early bird saving available online. Further information including a detailed agenda and full speaker line-up is available at http://www.in-vitro-diagnostics.co.uk/ein *Source: https://www.visiongain.com/Report/1750/Medical-Devices-Leader-Series-Top-In-Vitro-Diagnostics-(IVD)-Companies-2017-2027 Contact Information: For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, May 22, 2017 --( PR.com )-- With just 3 weeks to go, SMi Group have released an attendee list featuring a global audience of regulatory bodies, scientists, medical device experts and industry leaders for In Vitro Diagnostics 2017, set to take place in Central London this June. The international gathering emphasises a growing IVD market which is expected to reach $122.9bn by 2017. *Nations confirmed to attend include Belgium, France, Germany, Netherlands United Kingdom, UAE & USA.A snapshot of organisations confirmed to join include:Arkray Inc, Berlin Heart A G, BSI, Cytocell Ltd, Dekra, GS1, Immucor, IQ Products, Lifescan (J&J), LNE/G-MED, LRQA, Meridian Bioscience, MET, MHRA, Ortho Clinical Diagnostics, Procorre, Qarad Bvba, Qserve Consultancy, SPD Ltd., Tuv Rheinland, TUV SUD AB, UL International and more.View 2017 Attendee ListThe agenda will address questions such as:How can IVD manufacturers prepare for the new IVD regulation?How the change in classifications will impact the industry.What are the best strategies and approaches to meeting the requirements for clinical evidence?For those looking to attend there is currently a £100 early bird saving available online.Further information including a detailed agenda and full speaker line-up is available at http://www.in-vitro-diagnostics.co.uk/ein*Source: https://www.visiongain.com/Report/1750/Medical-Devices-Leader-Series-Top-In-Vitro-Diagnostics-(IVD)-Companies-2017-2027Contact Information:For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.ukAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


News Article | May 23, 2017
Site: www.prnewswire.com

Molecular HLA typing methods allow more precise matching between donor and recipient and is especially critical to bone marrow or HSCT transplant outcomes. Allogenic HSCT transplantation is a relatively high growth procedure area compared to solid organ transplantation and is a leading area of application for molecular HLA typing. Polymorphism in the human major histocompability complex (MHC) or HLA system is exceedingly complex for serological methods and is best captured by directly assaying genetic sequence. The molecular HLA typing market is provided for various regions, and forecasts are made to 2021. In addition the report discusses trends affecting the molecular transplant matching market.  Successful solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants require histocompatibility between the recipient and donor. Autologous transplantation using hematopoietic cells from the same patient (donor and recipient) is increasingly common and eliminates the need to screen for histocompatibility. However, solid organ transplants and HSCT allografts from another donor requires histocompatibility confirmed by human leukocyte antigen (HLA) testing outside of genetically identical twins. Proteins encoded by HLA system genes function as unique cell surface markers that regulate immune system recognition of foreign cells such as pathogens and tumor cells. Incompatibility between donor and recipient HLA systems or between donor tissue and recipient antibodies can result in severe complications such as transplant rejection. Testing of donor and recipient HLA systems is essential in cases of allograft between unrelated and even siblings. The most common forms of HLA typing are serological testing of HLA antigens and antibodies and detection of HLA alleles using a variety of molecular diagnostic techniques. Next-generation sequencing (NGS) is expected to develop into a leading option for the determination of HLA alleles. Key Topics Covered: 1: Executive Summary 2: Transplant Matching And Molecular Technology 3: Molecular Transplant Diagnostics Market And Market Share Analysis 4: Company Profiles - CareDx - Sequencing - Molecular HLA Typing - Illumina - Sequencing - Translational Research - Clinical Assay Development - Industry Lab-Developed Tests - Arrays - Immucor - Transfusion Diagnostics - Transplant Diagnostics - Immucor Dx Laboratory Service - Roche Diagnostics - Molecular Diagnostics - Thermo Fisher Scientific - Transplant Diagnostics - qPCR - Sequencing For more information about this report visit http://www.researchandmarkets.com/research/5zxkck/transplant Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/transplant-matching-molecular-diagnostics-market-2017-2021---research-and-markets-300462450.html


Trademark
Immucor Inc. | Date: 2013-08-27

COMPUTER SOFTWARE AND MIDDLEWARE FOR USE IN FACILITATING DATA ACCESS AND ARCHIVING ACROSS INSTRUMENTS, PLATFORMS AND APPLICATIONS IN THE FIELD OF IMMUNOHEMATOLOGY.


Trademark
Immucor Inc. | Date: 2013-08-27

COMPUTER SOFTWARE AND MIDDLEWARE FOR USE IN FACILITATING DATA ACCESS AND ARCHIVING ACROSS INSTRUMENTS, PLATFORMS AND APPLICATIONS IN THE FIELD OF IMMUNOHEMATOLOGY.


Trademark
Immucor Inc. | Date: 2016-03-30

instruments used in blood bank laboratories for testing parameters useful in human blood transfusions.


Trademark
Immucor Inc. | Date: 2016-03-30

instruments used in blood bank laboratories for testing parameters useful in human blood transfusions, namely blood group typing apparatus.


Trademark
Immucor Inc. | Date: 2013-10-14

chemical and biochemical reagents, assays and kits comprising diagnostic reagents for research and clinical laboratory use. diagnostic reagents, diagnostic assays and kits comprising diagnostic reagents for medical diagnostic use; in-vitro diagnostic test kits comprising primarily immunodiagnostic reagents for use in measuring various blood parameters. laboratory instruments for analyzing blood and tissue samples for medical use.


Trademark
Immucor Inc. | Date: 2012-10-02

DNA reference samples for evaluating the accuracy of assays used in hematology testing.


Trademark
Immucor Inc. | Date: 2015-04-21

hematology testing kits for use in the detection of human antigens comprised primarily of medical reagents and assays for the testing of body fluids for research purposes.

Loading Immucor Inc. collaborators
Loading Immucor Inc. collaborators